Objective: This study aims to determine whether vitamin D levels are associated with menopause-related symptoms in older women.
M any women experience menopause-related symptoms long after the final menstrual period. For example, women often experience hot flashes 1<7 for 4 to 10 years after menopause. 8<10 Many women also have mood disturbances, although their link with menopause is less clear. 1,6,7,11<16 These symptoms can be severe enough to negatively impact quality of life, work performance, and personal relationships. 1,17<20 Current treatments of menopause-related symptoms, such as menopausal hormone therapy (HT), antidepressants, and anticonvulsants, may have significant adverse effects and serious long-term adverse consequences. 21<23 After discontinuation of treatment, symptoms may recur or even develop de novo. 24, 25 Recognizing possible mechanisms underlying menopause-related symptoms may lead to the development of new therapeutic strategies.
Calcium balance studies have shown that calcium absorption declines with menopause. 26 Because 25-hydroxyvitamin transition through menopause. 28 We therefore hypothesized that vitamin D levels may be associated with menopauserelated symptoms.
We are unaware of any previous data on this association in postmenopausal women. However, we found a small study of breast cancer conducted among middle-aged women taking aromatase inhibitors. 29 Although the hot flashes occurring with aromatase inhibitor therapy are different in etiology from menopause-related vasomotor symtpoms, breast cancer patients who had higher 25(OH)D levels (966 ng/mL) had fewer hot flashes and other symptoms compared with women with lower vitamin D levels.
Some biological data suggest that a link between vitamin D and menopause-related symptoms is plausible. Vitamin D can protect against experimental serotonin depletion in rats, 30 and menopausal decline in serotonin, a neurotransmitter with known effects on thermoregulation, may be a contributor to hot flashes. 31<33 In addition, estrogen increases the activity of the enzyme responsible for activating vitamin D 34 ; thus, declining estrogen levels during the menopausal transition could lead to symptoms of vitamin D deficiency. Indeed, vitamin D supplementation can improve mood in nonmenopausal populations. 29,35<37 Based on the totality of evidence from limited data, we hypothesized that higher levels of vitamin D would be associated with fewer menopause-related symptoms. To test this hypothesis, we examined the cross-sectional association between baseline serum 25(OH)D levels and menopausal symptoms in a subset of women who participated in the Women's Health Initiative (WHI) Calcium and Vitamin D (CaD) trial.
METHODS
This article presents post hoc secondary analyses of the association between serum 25(OH)D concentrations and menopause-related symptoms among participants of the WHI CaD trial.
Sample selection
The WHI clinical trial (WHI-CT) enrolled postmenopausal women aged 50 to 79 years into randomized trials of menopausal HT, 38 dietary modification (DM), or both. 39 On year 1 or year 2 WHI-CT visit, HT and DM trial participants were also invited to participate in a randomized placebo-controlled CaD trial. 40 A total of 36,282 WHI-CT participants enrolled in the CaD trial. For our analysis, we drew participants from the CaD trial and used data from the CaD trial baseline visit. A subset of these women (N = 4,785) had vitamin D levels determined as part of separate unrelated case-control studies; we included in our analysis only controls (N = 1,407) from these studies. 41<43 We excluded women randomized to HT as part of the WHI trial, women with possible medical conditions associated with vitamin D deficiency (after a malabsorption diet, colitis, bowel resection, pancreatic disease, current gall bladder problems, and liver disease), or women with conditions that would influence vitamin D supplementation (high blood calcium or incident cancer). Of the remaining 26,104 eligible participants, 530 had 25(OH)D levels and data on important potential confounders (described later; Fig.) . These 530 women served as the final analytic sample; 528 of these women had at least one symptom of mild severity.
The Institutional Review Board at each participating institution approved all protocols and consent forms. All women provided a signed informed consent form.
Data collection Menopause-related symptoms
At the CaD trial baseline visit, participants provided data on menopause-related symptoms via questionnaires, 7 which contained a checklist based on the Postmenopausal Estrogen/ Progestin Interventions Trial symptom tool 44 and other national surveys and clinical trials. 45 The psychosocial forms containing these symptom items were reviewed for content validity by nationally recognized behavioral and clinical experts and were pretested extensively on age-appropriate women from diverse racial/ethnic groups. 25 For this analysis, the following symptoms were analyzed: hot flashes, night sweats, dizziness, heart racing or skipping beats, tremors, feeling restless or fidgety, feeling tired, difficulty concentrating, forgetfulness, mood swings, vaginal dryness, breast tenderness, headaches or migraines, waking up at night, waking earlier than planned, trouble falling back to sleep after waking earlier than planned, overall typical sleep quality, restless sleep, and energy level. These symptoms have been associated with menopause in previous research. For most of the symptoms, participants rated severity on a 4-point scale: 1, did not occur; 2, did not interfere with usual activities (mild); 3, interfered somewhat with usual activities (moderate); 4, so bothersome that usual activities could not be performed (severe). For sleep symptoms, participants rated how often they occurred during the past 4 weeks (from none to five or more times per week).
Our primary outcome was total number of symptoms of any severity (mild, moderate, or severe; range, 0-20). Secondary outcomes included the energy/fatigue and emotional wellbeing subscales of the 36-item Short-Form Health Survey (where higher scores indicate better health; range, 0-100) 46, 47 and a sleep disturbance construct. 48 The latter was created from five questions on sleep (trouble falling asleep, waking up several times at night, waking earlier than planned, trouble falling back to sleep after waking earlier than planned, and overall typical sleep); the summary score ranged from 0 to 20, with higher scores indicating greater sleep disturbance. We also examined associations between 25(OH)D levels and each individual symptom (of any severity) on the checklist.
Serum 25(OH)D assay
Serum was drawn at the CaD trial baseline visit (year 1 or year 2 of clinical trials), processed, and stored at j80-C, as previously described. 42 Serum 25(OH)D concentrations (nmol/L) were measured using the DiaSorin LIAISON chemiluminescence method (DiaSorin, Stillwater, MN). The coefficient of variation, which was determined using blinded controls, was 11.8%. 49 
Potential confounders
At the WHI-CT screening, participants self-reported data on demographics (race, education) and current or prior medical conditions (thyroid disorders). At the CaD trial baseline, participants self-reported demographics (ie, age, time since menopause), lifestyle factors (ie, physical activity, smoking), and ultraviolet (UV) exposure (ie, Langley's measure of UV exposure) and underwent physical measurements (ie, height and weight to calculate body mass index). 40 A standardized, in-person, interviewer-administered form was used to collect information on the dose, frequency, and duration of current supplements (ie, calcium, vitamin D) and medications (ie, menopausal HT, selective serotonin reuptake inhibitors/serotoninnorepinephrine reuptake inhibitors, selective estrogen receptor modulators, hypnotics/sedatives) at the CaD trial baseline. 50, 51 If data were not available at the CaD trial baseline (year 1 visit), data from the WHI-CT screening were used.
At the WHI-CT screening, intake of dietary CaD during the past 3 months was estimated from a self-administered food frequency questionnaire specifically designed for the WHI. 52 The food frequency questionnaire was also administered at the CaD trial baseline (year 1 of the WHI-CT), but only in the DM trial. Therefore, dietary vitamin D data collected at the CaD trial baseline (concurrent with the time that serum was obtained to determine 25(OH)D concentrations) were used when possible; otherwise, reported dietary vitamin D intake at screening was used. As previously reported, the Pearson correlation coefficient for dietary vitamin D intake among DM trial participants at baseline and year 1 was 0.59 (P G 0.0001). 49 
Statistical methods
We examined the cross-sectional association between 25(OH)D levels and symptoms. We examined 25(OH)D cutpoints based on current clinical definitions of vitamin D deficiency, insufficiency, and sufficiency (G25, 25 to G50, 50 to G75, and Q75 nmol/L) 53 These cutpoints were similar to quartile cutpoints.
We compared baseline characteristics according to 25(OH)D category, using W 2 tests of association for categorical variables and analysis of variance F tests for continuous variables.
Symptom total (primary outcome) was normally distributed and therefore modeled as a continuous outcome according to 25(OH)D status, using general linear models. The referent was 75 nmol/L or more of 25(OH)D. These results were adjusted for age and race and then adjusted for multiple confounding variables chosen a priori based on literature review and expert opinion about factors associated with menopausal symptoms, vitamin D status, or both. These included time since menopause, education, body mass index category, smoking status, UV exposure, HT at screening (personal history of HT use at screening visit), trial arm (HT or DM), and CaD intake (through diet and supplementation).
Using logistic regression, we estimated the odds ratio of having each individual symptom according to 25(OH)D status (G25, 25 to G50, 50 to G75, and Q75 nmol/L), with the highest cutoff as referent (Q75 nmol/L). We first adjusted for race and age and then adjusted the models for the potential confounders listed previously. We also examined the relationship between continuous 25(OH)D levels and continuous number of symptoms and composite symptom scores using linear regression.
We performed multiple imputation analysis as a sensitivity analysis to retain the 1,407 women with 25(OH)D levels, regardless of whether they had complete data on confounders.
For both logistic regression and linear models, we examined P values, adjusting for multiple comparisons for all analyses using a 5% false discovery rate and the Benjamini-Hochner method. 54 This study is a post hoc analysis of an existing data set with a fixed sample size. Assuming that the total number of symptoms was the primary outcome of interest and the parameter of interest was the regression coefficient of 25(OH)D, we conducted power analyses for two-tailed linear multiple regression. With 16 predictors and 530 participants, we had 80% power at an > of 0.05 to detect an effect size of 0.014. Thus, we were able to detect a 0.014 difference in symptoms for each unit change in 25(OH)D level.
RESULTS

Baseline characteristics
Women were, on average, 66 years of age and almost 16 years from menopause. Participants' age, time since menopause, education, UV exposure, HT use pattern at screening, and randomization to DM trial arm did not differ by 25(OH)D status (Table 1) . A higher percentage of nonwhite obese nonsmokers with lower activity levels and lower CaD intake (especially from supplements) was observed in the lower two 25(OH)D categories. There were no differences in the use of relevant nonhormonal medications (ie, serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, selective estrogen receptor modulators, hypnotics/sedatives) among 25(OH)D categories, although few women used these medications (G5% of women took at least one of these medications; data not shown). There was also no difference in the distribution of thyroid diseases among categories (only 1.8% and 15% had ever had overactive or underactive thyroid diseases, respectively; data not shown).
Women had 0 to 17 symptoms of at least mild intensity (mean [SD], 5.9 [3.3] ; median [interquartile range], 5 [5] ). Only 87 women (16.3%) reported hot flashes, and 109 women (20.4%) reported night sweats.
Association of vitamin D status with overall number of symptoms and composite measures of menopause-related symptoms
We observed no statistically significant association between total number of menopausal symptoms and 25(OH)D status in age-and race-adjusted (P = 0.11) or fully adjusted (P = 0.06) models (Table 2) . Similarly, we observed no significant association between 25(OH)D status and scores on composite measures of sleep disturbance, emotional well-being, and energy/ fatigue in age-and race-adjusted (P's 9 0.05) or fully adjusted (P's 9 0.10) models. Any associations of borderline statistical significance were no longer significant after adjustment for multiple comparisons (data not shown).
Using linear regression, we observed a statistically significant association between continuous 25(OH)D levels and total number of symptoms. Vitamin D levels were not associated with any composite symptom score. For total number of symptoms, each 1-nmol/L increase in 25(OH)D level resulted in 0.01 fewer total number of symptoms. This degree of symptom reduction is unlikely to be clinically significant. In addition, the association was no longer statistically significant after adjustment for multiple comparisons.
Association between 25(OH)D status and individual menopause-related symptoms
No individual menopause-related symptoms were significantly associated with 25(OH)D status after adjustment for multiple comparisons (Table 3) .
DISCUSSION
Among postmenopausal women with a mean age of 66 years and 15.9 years from menopause, we found a borderline association between total number of menopause-related symptoms and 25(OH)D levels. However, the effect size was clinically insignificant, and the associations were no longer significant after correction for multiple comparisons.
We are unaware of any other studies that have examined the association between 25(OH)D levels and menopause-related symptoms. Among breast cancer patients taking aromatase inhibitors, low 25(OH)D levels were associated with a greater prevalence of symptoms, especially vasomotor symptoms 29 ; however, hot flashes in breast cancer patients are different from those in postmenopausal women. Furthermore, the mean (SD) age of our population, 66.2 (6.8) years, was higher than that in the study of women with breast cancer (56 y), and we excluded women with a history of cancer. In fact, only 27% of the women in our study experienced any hot flashes or night sweats. This low symptom prevalence could be attributable to women having a mean age of 66 years and being almost 16 years from menopause; in addition, women with severe menopause-related symptoms were discouraged from participating because of the possibility that they would be randomized to placebo.
We had hypothesized that because estrogen increases the activity of the enzyme responsible for activating vitamin D, 34 low estrogen levels in postmenopausal women could exacer-bate the symptoms of subclinical vitamin D deficiency, including mood disturbances. Previous studies have found that vitamin D supplementation can improve such things as mood in nonmenopausal populations. 29 ,35<37 However, we did not find an association between 25(OH)D status and composite scores on sleep, emotional well-being, or energy/fatigue constructs in our population of postmenopausal women.
Our study had several limitations. This was a post hoc analysis of women who had vitamin D testing performed as part of three nested case-control studies of fracture, breast cancer, and colorectal cancer. Participants were matched on age, race/ethnicity, blood draw date, and clinic center at CaD randomization. The breast cancer nested case-control study was also matched on HT and DM trial arm participation. This subset selection increased the age of the study cohort and reduced the number of women with symptoms related to early menopause (such as hot flashes and night sweats; Fig.) . Three quarters of our participants were more than 10 years from menopause, and women in this study who were still experiencing symptoms may not be representative of the general population of women who experience symptoms during the transition through menopause. The WHI used a brief self-report instrument to collect data on menopausal symptoms. Only the presence and broad severity of the symptoms could therefore be assessed. Given that few women with vasomotor symptoms were included in this sample and the lack of rigorous measurement of vasomotor symptoms, we cannot exclude a different finding in a younger population with more rigorous monitoring of hot flashes.
Because no data on a possible association between 25(OH)D levels and menopause-related symptoms were available, we examined multiple symptoms. This increased the possibility that we would find an association by chance; indeed, any associations we had found were no longer significant after we corrected for multiple comparisons. On the other hand, the number of women who were included in our final sample was relatively small, and only 27% of these women experienced vasomotor symptoms. This low number of women with vasomotor symptoms could have limited our ability to find an association between vasomotor symptoms and 25(OH)D levels. We performed sensitivity analyses using multiple imputation to examine all 1,407 women with 25(OH)D levels (not just those who had data on confounders) and obtained similar null findings. We did not stratify by time since menopause, and it is possible that 25(OH)D levels may be associated with menopausal symptoms in women who are closer to the onset of menopause. Because this was a post hoc analysis, conclusions can only be considered hypothesis-generating.
CONCLUSIONS
Our data do not support the hypothesis that vitamin D status is associated with menopause-related symptoms in postmenopausal women with a mean age of 66 years. We cannot exclude an association in younger women who are more symptomatic.
